Skip to main content

Table 4 Use of healthcare resources per patient per year according to antimuscarinic treatment in adjusted analysis*

From: Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

Resource, mean (95% CI†)

Antimuscarinic

PValue

 

Fesoterodine

Solifenacin

Tolterodine

 
 

(n = 302)

(n = 952)

(n = 717)

 

Medical visits, n

13.2 (12.3; 14.1)

15.1 (14.5; 15.9)‡

16.4 (15.5; 17.5)‡§

<0.001

Primary care

11.6 (10.8; 12.5)

12.9 (12.2; 13.7)‖

14.2 (13.2; 15.3)‡

0.006

Specialist

1.5 (1.4; 1.6)

2.0 (2.0; 2.1)‡

2.0 (1.9; 2.0)‡

<0.001

Emergency room

0.1 (0.1; 0.1)

0.2 (0.2; 0.2)‡

0.3 (0.3; 0.3)‡¶

<0.001

Analytical tests, n

0.8 (0.7; 0.9)

0.7 (0.7; 0.8)

0.7 (0.6; 0.8)

0.686

X-ray, n

0.3 (0.3; 0.4)

0.4 (0.3; 0.4)

0.4 (0.4; 0.5)

0.157

Complementary tests, n

0.2 (0.1; 0.3)

0.2 (0.1; 0.2)

0.2 (0.1; 0.3)

0.849

Hospital stays, days

0.1 (0.1; 0.2)

0.2 (0.1; 0.2)

0.2 (0.1; 0.2)

0.221

  1. *Adjusting for geographic area, age, sex, medication possession ratio, time since diagnosis and Charlson co-morbidity index.
  2. †95% bootstrap confidence interval bias corrected.
  3. ‡ P < 0.01 vs fesoterodine.
  4. § P < 0.05 vs solifenacin.
  5. ‖ P < 0.05 vs fesoterodine.
  6. P < 0.001 vs solifenacin.
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us